Chapter 2. Antimicrobial Resistance
Human Surveillance
Key Findings
The Provincial Public Health Laboratories forwarded a total of 4,129 Salmonella isolates (171 serovars) to the National Microbiology Laboratory, Public Health Agency of Canada, for phage typing and susceptibility testing.
Susceptibility testing was carried out on 8 serovars: Enteritidis, Heidelberg, Newport, Paratyphi A, Paratyphi B, Typhi, Typhimurium, and 4,[5],12:i:-. All other isolates have been stored for future susceptibility testing. Summary results are only provided for these serotypes based on analysis conducted on 2,565 isolates.
Human patients aged 50-69 years represented the most common age group for which Salmonella isolates were tested (15%, 564/2,565). Ontario was the province for which the largest proportion of isolates was received (41%, 1,547/2,565). Provincial incidence rates for specific Salmonella serovar infections can be found in Figure 2.
Enteritidis (n = 1,179)
Most common phage types (PT) recovered: PT 8 (31%, 367/1,179), PT 13a (15%, 181/1,179) and atypical Footnote 7 (11%, 134/1,179). Three percent of isolates were recovered from blood; significant increases in isolates from urine were observed in 2012 (3%, 40/1,179) compared to 2011 (2%, 18/951).
Significant increase in resistance to ciprofloxacin was observed compared to 2011, when no resistance was observed. Ten isolates had resistance in 2012 (1%, 10/1,179) compared to 1 isolate observed in 2009 (less than 1%, 1/1,092), the only other time when observed. Different PT were involved (22, 34a, 8, and atypical).
Overall a significant reduction in nalidixic acid resistance was observed between 2011 (15%, 146/951) and 2012 (12%, 145/1,179). Significant decrease was seen in Ontario from 21% (50/236) to 14% (53/374). A total of 9 isolates resistant to ciprofloxacin did not exhibit resistance to nalidixic acid. Less than 1% of the Enteritidis isolates (2/1,179) were resistant to both nalidixic acid and ceftriaxone.
The most common resistance pattern was nalidixic acid (11%, 124/1,179) mainly consisting of PT atypical (40%, 50/124) and PT 1 isolates (24%, 30/124). The pattern involving the greatest number of antimicrobials was AMP-AZM-FOX-TIO-CRO-CIP-GEN-KAN-NAL-SSS-TET-SXT (1 PT 8 isolate from Nova Scotia).
Heidelberg (n = 555)
Most common PT recovered included: PT 19 (54%, 298/555), PT 29 (21%, 114/555) and PT 18 (5%, 25/555) (Figure 3). Phage type 19 significantly increased compared to 2011 (45%, 171/377). Five percent (25/555) of isolates were recovered from urine and 10% (55/555) from blood.
Significant changes in resistance to specific antimicrobials and in specific provinces were observed:
Ceftiofur
- Decrease from 33% (125/377) in 2011 to 27% (150/555) in 2012
- Increase from 13% (57/430) in 2006 to 27% (150/555) in 2012
- Decrease from 33% (181/556) in 2004 to 27% (150/555) in 2012
- Increase in British Columbia from 12% (2/17) in 2011 to 64% (25/39) in 2012
- Decrease in Ontario from 35%, (49/140) in 2011 to 16% (35/222) in 2012
Amoxicillin-clavulanic acid
- Decrease from 33% (125/377) in 2011 to 25% (141/555) in 2012
- Increase in British Columbia from 12% (2/17) in 2011 to 49% (19/39) in 2012
- Decrease in Ontario from 35% (49/140) in 2011 to 16% (35/222) in 2012
Ceftriaxone
- Decrease from 33% (125/377) in 2011 to 26% (151/555) in 2012
- Increase in British Columbia from 12% (2/17) in 2011 to 67% (26/39) in 2012
- Decrease in Ontario from 35% (49/140) in 2011 to 16% (35/222) in 2012
Ampicillin
- Decrease from 41% (153/377) in 2011 to 34% (183/555) in 2012
- Decrease from 39% (168/430) in 2006 to 33% (183/555) in 2012
- Decrease from 45% (250/556) in 2004 to 33% (183/555) in 2012
- Increase in British Columbia from 24% (4/17) in 2011 to 74% (29/39) in 2012
- Decrease in Ontario from 44% (61/140) in 2011 to 22% (49/222) in 2012
For all years combined, 81% (813/995) of resistance to ceftiofur is observed among PT 29, PT 41, PT 4, PT 32, and PT 19. Approximately 70% (2,353/3,405) of all ceftiofur-susceptible strains were among PT 19, 26, atypical, 11, and 5. Overall, resistance to ceftiofur was driven by the increases or decreases of PT 29 among Heidelberg isolates (Figure 3).
The most common resistance pattern was A2C-AMP-CRO (24%, 135/555), followed by the AMP pattern (4%, 24/555). The pattern involving the greatest number of antimicrobials was A2C-AMP-CRO-STR-SSS (1 PT 29 isolate from Manitoba).
Significant changes in age have occurred between 2011 and 2012: 18-29 age group has significantly increased from 9% (34/377) to 14% (79/555) of Heidelberg isolates, while those from patients 70 years and older has significantly decreased from 10% (39/377) to 3% (19/555) (Figure 5).
Newport (n = 149)
The most common PT recovered included: PT 9 (17%, 26/149), atypical (15%, 23/149), and PT 2 (15%, 22/149). Three percent (4/149) of isolates were recovered from urine and 2% (3/149) from blood.
In 2011, decreases were observed in resistance to the A2C-AMP-CRO pattern (amoxicillin-clavulanic acid, ceftiofur, ceftriaxone, ampicillin, and cefoxitin) for British Columbia (21%, 3/14) and Alberta (15%, 3/20) when compared to 2012 (5%, 1/19 and 1/20, respectively). In 2012, nalidixic acid resistance was observed this year in 1 isolate each from Alberta, Saskatchewan, and Ontario only.
There was no nalidixic acid resistance observed in 2011 and only in 1 isolate in 2010.
The most common resistance pattern was ACSSuT-A2C-CRO (5%, 8/149), followed by the NAL (1%, 2/149) and the CHL-KAN-STR-SSS-TET-SXT (1%, 2/149) patterns. The pattern involving the greatest number of antimicrobials was ACSSuT-A2C-CRO-SXT (1 PT 17a isolate from Québec).
Changes in patient age have occurred between 2011 and 2012: the proportion of Newport isolates belonging to the 18-29 age group represented 9% (9/149) of all cases, the lowest percentage observed since 2003 (Figure 6). The total number of isolates in the 30-49 and 50-69 age categories increased between 2011 (17%, 33/193; 17%, 32/193 respectively) and 2012 (20%, 29/149; 21%, 31/149 respectively).
Paratyphi A (n = 38) and Paratyphi B (n = 0)
There were no Paratyphi B isolates received by CIPARS for susceptibility testing in 2012. Sixty-three percent of Paratyphi A isolates (24/38) were recovered from blood samples.
Resistance to ciprofloxacin was observed in 1 Paratyphi A isolate from British Columbia (Table 1). This resistance was previously observed in 1 isolate from Nova Scotia in 2010. Resistance to nalidixic acid significantly increased from 42% (5/12) in 2011 to 95% (36/38) in 2012 (Figure 9).
Typhi (n = 144)
The most common phage types recovered were PT UVS (I+IV) (23%, 33/144), PT E1 (21%, 30/144), PT E9 var. (15%, 21/144). Sixty-nine percent (99/144) of isolates were recovered from blood samples and 1% (1/144) from urine.
Overall, there was a significant increase in ciprofloxacin resistance from 3% (5/197) in 2011 to 10%, (14/144) observed in 2012. A significant increase in ciprofloxacin resistance from 4% (4/103) in 2011 to 17% (13/77) was also observed among isolates from Ontario in 2012.
The most common resistance pattern was resistance to the NAL pattern (58%, 83/144), followed by resistance to AMP-CHL-NAL-STR-SSS-SXT (15%, 22/144).
Significant increases in the proportion of Typhi cases between the ages of 5-12 years were observed from 10% (18/179) in 2010 to 19% (28/144) in 2012 (Figure 7). Smaller changes were also observed among the age group of less than 5 years which increased from 2011 (6%, 13/197) to 2012 (10%, 15/144). A slight decrease among the age group of 50-69 years was observed between 2010 (9%, 17/179) and 2012 (5%, 7/144).
Typhimurium (n = 378)
The most common PT recovered was PT 108 (19%, 70/378), followed by atypical (16%, 60/378) and PT 104 (11%, 43/378). Significant decreases have been observed in PT 104 between 2003 (24%, 146/605) and 2012 (11%, 43/378).
Ciprofloxacin resistance was observed in 3 isolates in 2012 (2 from Ontario and 1 from Newfoundland and Labrador). No resistance was observed in 2011.
Azithromycin resistance was observed in 2 isolates from Ontario (PT 120 and atypical). No resistance to azithromycin was observed in 2011, the first year that susceptibility testing was undertaken for this antimicrobial. Azithromycin resistance was observed in the following resistance patterns: AZM-KAN-TET and AZM-CHL-GEN-KAN-STR-SSS-TET-SXT.
The most common resistance pattern was resistance to ACSSuT (14%, 52/378), followed by resistance to ACKSSuT (3%, 11/378). The pattern involving the greatest number of antimicrobials was ACSSuT-A2C-CRO-GEN-SXT (1 PT U310 isolate from Alberta).
4,[5],12:i:- (n = 122)
The most common PTs recovered were PT 193 (24%, 29/122), PT U291 (21%, 26/122) and atypical (17%, 21/122). Two percent (2/122) of isolates were recovered from urine samples and 1% (1/122) from blood.
Overall, significant decreases were observed among the following antimicrobials between 2011 and 2012:
- Amoxicillin resistance decreased from 12% (12/104) to 3% (3/122) (Figure 9).
- Ceftiofur resistance decreased from 12%, (12/104) to 2% (2/122). This decrease in Ontario was from 17% (4/23) to 2% (1/55) (Figure 9).
- Ceftriaxone resistance decreased from 12% (12/104) to 2% (2/122).
- Cefoxitin resistance decrease from 12% (12/104) to 2% (2/122).
Azithromycin resistance was observed in 3 isolates (1 PT 193 and 1 PT 35 from Ontario, and 1 PT 35 from Prince Edward Island). Resistance to azithromycin was observed in the following resistance patterns: AZM-KAN-TET (1 PT 35 from Ontario and 1 PT 35 from Prince Edward Island) and ACKSSuT-AZM-CIP-GEN-NAL-SXT (1 PT 193 isolate from Ontario).
The most common resistance pattern was AMP-STR-SSS-TET (25%, 31/122), followed by resistance to the TET pattern (9%, 11/122). The pattern involving the greatest number of antimicrobials was ACKSSUT-AZM-CIP-GEN-NAL-SXT (1 PT 193 isolate in Ontario).
Significant changes were observed among cases between the ages of 13-17 years which increased from 1% (1/104) in 2011 to 7% (9/122) of 4,[5],12:i:- isolates in 2012 (Figure 8). Smaller changes were also observed among the 50-69 age class which increased from 8%, (8/104) in 2011 to 16% (20/122) in 2012.
Serovar and Phage Type Distribution
Figure 2. Provincial incidence rates for specific Salmonella serovars in 2012
Text Equivalent - Figure 2
| Province | Enteritidis | Heidelberg | Newport | Paratyphi A and B | Typhi | Typhimurium | 4,[5],12:i:- |
|---|---|---|---|---|---|---|---|
| BC | 7.7 | 1.7 | 0.4 | 0.5 | 0.7 | 1.1 | 0.1 |
| AB | 9.2 | 1.9 | 0.5 | 0.3 | 0.4 | 1.3 | 0.8 |
| SK | 6.0 | 1.5 | 0.9 | 0.1 | 0.5 | 1.3 | 0.5 |
| MB | 5.0 | 1.9 | 0.2 | 0.0 | 0.6 | 1.5 | 0.6 |
| ON | 5.5 | 3.3 | 0.5 | 0.2 | 0.6 | 3.0 | 0.8 |
| QC | 3.5 | 3.2 | 0.3 | < 0.1 | 0.1 | 1.8 | 0.7 |
| NB | 8.5 | 5.0 | 0.8 | 0.0 | 0.1 | 0.9 | 0.7 |
| NS | 7.5 | 3.4 | 0.3 | 0.0 | 0.0 | 0.9 | 0.1 |
| PEI | 9.6 | 1.4 | 0.0 | 0.0 | 0.0 | 2.1 | 0.7 |
| NL | 5.6 | 3.3 | 0.2 | 0.0 | 0.0 | 0.6 | 0.4 |
Provincial abbreviations are defined in the Preamble.
No S. Newport isolates were received from Prince Edward Island.
No S. Typhi isolates were received from Nova Scotia, Prince Edward Island, and Newfoundland and Labrador.
There were no Paratyphi B isolates received by CIPARS for susceptibility testing in 2012.
Figure 3. Temporal variations of the most common Salmonella Heidelberg phage types
Text Equivalent - Figure 3
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Phage type | ||||||||||
| 29 | 11% | 22% | 19% | 7% | 10% | 8% | 8% | 12% | 23% | 21% |
| 41 | 5% | 5% | 6% | 3% | 3% | 4% | 4% | 3% | 5% | 2% |
| 4 | 4% | 2% | 1% | < 1% | 0% | 0% | 1% | 1% | 1% | < 1% |
| 32 | 6% | 6% | 4% | 5% | 2% | 2% | 2% | 2% | < 1% | 1% |
| 19 | 35% | 34% | 36% | 37% | 35% | 54% | 46% | 43% | 45% | 54% |
| 26 | 9% | 3% | 4% | 4% | 7% | 2% | 3% | 7% | 2% | 2% |
| Atypical | 0% | 3% | 5% | 8% | 10% | 4% | 4% | 4% | 3% | 3% |
| 11 | 7% | 4% | 1% | 3% | 2% | 6% | 1% | 0% | 1% | 0% |
| 5 | 1% | 2% | 2% | 4% | 2% | 8% | 4% | 3% | 1% | 1% |
| Ceftiofur resistance | 22% | 33% | 29% | 13% | 15% | 14% | 14% | 19% | 33% | 27% |
For Salmonella Heidelberg, the majority of phage types were susceptible to ceftiofur, with the exception of PT 29 which contributed primarily to the observed ceftiofur resistance.
Figure 4. Temporal variations of age groups represented within Salmonella Enteritidis isolates
Text Equivalent - Figure 4
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age class | ||||||||||
| Less than 5 | 9% | 10% | 7% | 7% | 6% | 9% | 7% | 6% | 5% | 6% |
| 5 to 12 | 9% | 13% | 11% | 9% | 10% | 5% | 9% | 8% | 6% | 7% |
| 13 to 17 | 4% | 5% | 6% | 5% | 5% | 18% | 5% | 5% | 4% | 4% |
| 18 to 29 | 13% | 17% | 17% | 18% | 16% | 22% | 15% | 13% | 13% | 14% |
| 30 to 49 | 31% | 28% | 20% | 35% | 28% | 7% | 22% | 17% | 18% | 14% |
| 50 to 69 | 18% | 17% | 19% | 21% | 15% | 17% | 19% | 15% | 17% | 17% |
| 70 or older | 5% | 7% | 9% | 5% | 6% | 6% | 9% | 6% | 5% | 8% |
Figure 5. Temporal variations of age groups represented within Salmonella Heidelberg isolates
Text Equivalent - Figure 5
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age class | ||||||||||
| Less than 5 | 17% | 17% | 16% | 10% | 7% | 8% | 12% | 12% | 13% | 11% |
| 5 to 12 | 18% | 14% | 17% | 10% | 8% | 11% | 10% | 7% | 7% | 8% |
| 13 to 17 | 6% | 6% | 6% | 6% | 5% | 4% | 6% | 3% | 6% | 3% |
| 18 to 29 | 13% | 17% | 17% | 16% | 15% | 21% | 14% | 14% | 9% | 14% |
| 30 to 49 | 17% | 20% | 16% | 35% | 32% | 19% | 14% | 12% | 12% | 12% |
| 50 to 69 | 12% | 13% | 11% | 14% | 11% | 10% | 13% | 11% | 15% | 14% |
| 70 or older | 9% | 9% | 10% | 9% | 8% | 9% | 14% | 6% | 10% | 3% |
Figure 6. Temporal variations of age groups represented within Salmonella Newport isolates
Text Equivalent - Figure 6
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age class | ||||||||||
| Less than 5 | 9% | 10% | 9% | 8% | 5% | 9% | 11% | 8% | 10% | 7% |
| 5 to 12 | 7% | 7% | 6% | 7% | 13% | 7% | 2% | 4% | 4% | 4% |
| 13 to 17 | 4% | 1% | 2% | 3% | 3% | 2% | 2% | 1% | 1% | 1% |
| 18 to 29 | 13% | 16% | 14% | 13% | 13% | 16% | 12% | 15% | 12% | 9% |
| 30 to 49 | 23% | 32% | 22% | 33% | 22% | 26% | 21% | 14% | 17% | 19% |
| 50 to 69 | 22% | 21% | 15% | 23% | 20% | 16% | 25% | 18% | 17% | 21% |
| 70 or older | 9% | 7% | 19% | 14% | 12% | 9% | 7% | 6% | 8% | 8% |
Figure 7. Temporal variations of age groups represented within Salmonella Typhi isolates
Text Equivalent - Figure 7
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age class | ||||||||||
| Less than 5 | 13% | 14% | 10% | 15% | 7% | 10% | 13% | 6% | 7% | 10% |
| 5 to 12 | 10% | 23% | 17% | 20% | 13% | 14% | 16% | 10% | 14% | 19% |
| 13 to 17 | 4% | 4% | 11% | 10% | 5% | 6% | 8% | 8% | 6% | 1% |
| 18 to 29 | 25% | 22% | 31% | 19% | 28% | 21% | 26% | 16% | 18% | 18% |
| 30 to 49 | 31% | 23% | 21% | 26% | 31% | 32% | 19% | 16% | 13% | 16% |
| 50 to 69 | 4% | 8% | 7% | 9% | 6% | 8% | 6% | 9% | 7% | 5% |
| 70 or older | 3% | 5% | 3% | 2% | 2% | 2% | 4% | 1% | 2% | 1% |
Figure 8. Temporal variations of age groups represented within Salmonella 4,[5],12:i:- isolates
![Temporal variations of age groups represented within Salmonella 4,[5],12:i:- isolates](/content/dam/phac-aspc/migration/phac-aspc/cipars-picra/2012/assets/images/chap2-fig8-eng.jpg)
Text Equivalent - Figure 8
| Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age class | ||||||||||
| Less than 5 | 21% | 17% | 11% | 7% | 13% | 10% | 9% | 11% | 19% | 15% |
| 5 to 12 | 29% | 11% | 13% | 23% | 13% | 15% | 9% | 10% | 10% | 10% |
| 13 to 17 | 2% | 9% | 2% | 7% | 2% | 5% | 5% | 4% | 1% | 7% |
| 18 to 29 | 17% | 15% | 22% | 5% | 12% | 14% | 15% | 12% | 11% | 10% |
| 30 to 49 | 14% | 20% | 27% | 33% | 19% | 19% | 13% | 16% | 19% | 13% |
| 50 to 69 | 5% | 13% | 10% | 18% | 14% | 11% | 14% | 11% | 8% | 16% |
| 70 or older | 10% | 11% | 8% | 7% | 4% | 10% | 9% | 5% | 5% | 4% |
Multiclass Resistance
| Province/serovar | Numbers (%) of isolates |
Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | β-lactams | Folate pathway inhibitors | Macrolides | Phenicols | Quinolones | Tetracyclines | |||||||||||||||
| 0 | 1 | 2-3 | 4-5 | 6-7 | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | AZM | CHL | CIP | NAL | TET | ||
| British Columbia | |||||||||||||||||||||
| Enteritidis | 178 (57.6) | 151 | 22 | 1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22 | 6 | ||||||||
| Heidelberg | 39 (12.6) | 9 | 22 | 8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.26 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25 | 8 | ||||||||||
| Typhi | 33 (10.7) | 5 | 27 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28 | ||||||||||
| Typhimurium | 25 (8.1) | 15 | 2 | 1 | 7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 6 | 9 | ||||||
| Newport | 19 (6.1) | 16 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 3 | 3 | |||||||
| Paratyphi A and B | 12 (3.9) | 12 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 | |||||||||||||||||
| 4,[5],12:i:- | 3 (1) | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 1 | 3 | |||||||||||||
| Total | 309 (100) | 196 | 87 | 10 | 16 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.20 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.27 | 18 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | 13 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62 | 29 | ||
| Alberta | |||||||||||||||||||||
| Enteritidis | 179 (60.3) | 156 | 17 | 2 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | 4 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | 3 | |||||
| Heidelberg | 37 (12.5) | 18 | 15 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 3 | ||||||
| Typhimurium | 25 (8.4) | 12 | 4 | 9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | 13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 8 | 10 | |||||
| Newport | 20 (6.7) | 18 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | |||||||
| Typhi | 16 (5.4) | 2 | 8 | 6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | |||||||||||
| 4,[5],12:i:- | 15 (5.1) | 5 | 5 | 1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 4 | 10 | ||||||||||||
| Paratyphi A and B | 5 (1.7) | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | ||||||||||||||||||
| Total | 297 (100) | 211 | 51 | 11 | 24 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 | 30 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | 18 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32 | 27 | |||
| Saskatchewan | |||||||||||||||||||||
| Enteritidis | 65 (56) | 59 | 6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | |||||||||||||||||
| Heidelberg | 16 (13.8) | 7 | 9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | |||||||||||||
| Typhimurium | 14 (12.1) | 8 | 2 | 1 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 3 | ||||
| Newport | 10 (8.6) | 9 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | ||||||||||||
| 4,[5],12:i:- | 5 (4.3) | 1 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 4 | 4 | ||||||||||||||
| Typhi | 5 (4.3) | 2 | 1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | |||||||||||
| Paratyphi A and B | 1 (0.9) | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | ||||||||||||||||||
| Total | 116 (100) | 84 | 20 | 2 | 10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | 12 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 | 8 | |||
| Manitoba | |||||||||||||||||||||
| Enteritidis | 64 (50.8) | 53 | 9 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | 1 | ||||||||||
| Heidelberg | 24 (19) | 12 | 10 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | 1 | 1 | |||||||||
| Typhimurium | 19 (15.1) | 8 | 2 | 1 | 8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | 9 | 6 | 8 | |||||||||||
| 4,[5],12:i:- | 8 (6.3) | 5 | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 3 | |||||||||||||
| Typhi | 7 (5.6) | 7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | ||||||||||||||||||
| Newport | 2 (1.6) | 2 | |||||||||||||||||||
| Paratyphi A and B | 2 (1.6) | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | ||||||||||||||||||
| Total | 126 (100) | 80 | 32 | 5 | 9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | 12 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18 | 13 | |||
| Ontario | |||||||||||||||||||||
| Enteritidis | 374 (37.1) | 307 | 55 | 10 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 | 8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53 | 8 | ||||||||
| Heidelberg | 222 (22) | 163 | 51 | 8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.35 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.35 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.35 | 8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 5 | ||||||
| Typhimurium | 202 (20) | 149 | 5 | 11 | 36 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 47 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 34 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 46 |
| Typhi | 77 (7.6) | 7 | 54 | 2 | 14 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 | 16 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 | 15 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68 | |||||||||
| Newport | 64 (6.6) | 59 | 1 | 1 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 4 | |||||
| 4,[5],12:i:- | 55 (5.5) | 37 | 5 | 2 | 10 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 12 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 15 |
| Paratyphi A and B | 15 (1.5) | 2 | 13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | |||||||||||||||||
| Total | 1009 (100) | 724 | 184 | 34 | 65 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | 81 | 128 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.41 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.40 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.40 | 95 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 54 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.140 | 78 |
| Québec | |||||||||||||||||||||
| Enteritidis | 141 (35.4) | 106 | 29 | 4 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30 | 5 | |||||
| Heidelberg | 128 (32.2) | 90 | 35 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | |||||||
| Typhimurium | 71 (17.8) | 39 | 5 | 4 | 22 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | 27 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | 20 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | 28 | ||
| 4,[5],12:i:- | 27 (6.8) | 11 | 1 | 2 | 13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 1 | 14 | ||||||
| Newport | 24 (6.0) | 21 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 3 | 3 | ||||||||
| Typhi | 5 (1.3) | 5 | |||||||||||||||||||
| Paratyphi A and B | 2 (0.5) | 2 | 2 | ||||||||||||||||||
| Total | 398 (100) | 272 | 72 | 13 | 40 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.37 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.39 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.38 | 48 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 | 24 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36 | 50 | |
| New Brunswick | |||||||||||||||||||||
| Enteritidis | 64 (52.9) | 53 | 8 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | 3 | 6 | 3 | ||||||||||||
| Heidelberg | 38 (31.4) | 20 | 11 | 7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 2 | |||||||
| Typhimurium | 7 (5.8) | 2 | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | 5 | 1 | ||||||||||||||
| Newport | 6 (5.0) | 5 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 1 | 1 | 1 | |||||||||
| 4,[5],12:i:- | 5 (4.1) | 3 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | ||||||||||||
| Typhi | 1 (0.8) | 1 | |||||||||||||||||||
| Total | 121 (100) | 84 | 20 | 12 | 5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13 | 14 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 8 | ||||
| Nova Scotia | |||||||||||||||||||||
| Enteritidis | 71 (61.2) | 65 | 5 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 1 | |||||
| Heidelberg | 32 (27.6) | 24 | 7 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 | |||||||||||
| Typhimurium | 9 (7.8) | 6 | 1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 2 | 3 | ||||||||||
| Newport | 3 (2.6) | 3 | |||||||||||||||||||
| 4,[5],12:i:- | 1 (0.9) | 1 | |||||||||||||||||||
| Total | 116 (100) | 99 | 12 | 2 | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 | 4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 | 4 |
| Prince Edward Island | |||||||||||||||||||||
| Enteritidis | 14 (66.7) | 11 | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | 1 | 1 | |||||||||||||
| Typhimurium | 3 (14.3) | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 1 | 1 | |||||||||||||
| Heidelberg | 2 (9.5) | 2 | |||||||||||||||||||
| 4,[5],12:i:- | 1 (4.8) | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | ||||||||||||||||
| Paratyphi A and B | 1 (4.8) | 1 | 1 | ||||||||||||||||||
| Total | 21 (100) | 15 | 3 | 1 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | 2 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 3 | ||||||||
| Newfoundland and Labrador | |||||||||||||||||||||
| Enteritidis | 29 (55.8) | 27 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | 1 | |||||||||||||
| Heidelberg | 17 (32.7) | 8 | 9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | ||||||||||||
| Typhimurium | 3 (5.8) | 2 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | ||||||||
| 4,[5],12:i:- | 2 (3.8) | 2 | |||||||||||||||||||
| Newport | 1 (1.9) | 1 | 1 | ||||||||||||||||||
| Total | 52 (100) | 39 | 11 | 1 | 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 | 2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 | 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 | 3 | ||
Antimicrobial abbreviations are defined in the Preamble. |
|||||||||||||||||||||
Temporal Antimicrobial Resistance Summary
Figure 9. Temporal variations in resistance of Salmonella serovars from humans
| Serovar | Enteritidis | Heidelberg | Newport | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | '03 | '04 | '05 | '06 | '07 | '08 | '09 | '10 | '11 | '12 | '03 | '04 | '05 | '06 | '07 | '08 | '09 | '10 | '11 | '12 | '03 | '04 | '05 | '06 | '07 | '08 | '09 | '10 | '11 | '12 |
| Number of isolates | 352 | 549 | 612 | 710 | 910 | 1,258 | 1,092 | 995 | 951 | 1,179 | 608 | 556 | 409 | 430 | 318 | 290 | 381 | 476 | 377 | 555 | 175 | 152 | 142 | 146 | 127 | 177 | 136 | 135 | 193 | 149 |
| Antimicrobial | ||||||||||||||||||||||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | 4% | 2% | 3% | 2% | 3% | 2% | 2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35% | Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.45% | 47% | Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.39% | 30% | 32% | 33% | 32% | Significant differences (P ≤ 0.05) for a given antimicrobial.41% | Significant differences (P ≤ 0.05) for a given antimicrobial. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.33% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% | 11% | 9% | 12% | 5% | 3% | 2% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 0% | 1% | 0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.22% | Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.33% | 29% | Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.13% | 15% | 14% | 14% | 19% | Significant differences (P ≤ 0.05) for a given antimicrobial.33% | Significant differences (P ≤ 0.05) for a given antimicrobial. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.27% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% | 9% | 8% | 8% | 3% | 2% | 1% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 1% | 1% | 0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | 1% | 1% | 3% | 3% | 2% | 4% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 1% | 0% | 0% | 1% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19% | 23% | 9% | 20% | 18% | 13% | 10% | 10% | Significant differences (P ≤ 0.05) for a given antimicrobial.15% | Significant differences (P ≤ 0.05) for a given antimicrobial.12% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 1% | 2% | 1% | 0% | 1% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | 1% | 0% | 5% | 2% | 1% | 0% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% |
| Streptomycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 4% | 2% | 1% | 1% | 1% | 2% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12% | 8% | 8% | 13% | 10% | 7% | 7% | 6% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% | 12% | 10% | 13% | 5% | 2% | 3% | 4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% |
| Tetracycline | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | 5% | 2% | 4% | 6% | 2% | 1% | 2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15% | 16% | 11% | 13% | 7% | 6% | 5% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% | 13% | 10% | 18% | 9% | 4% | 4% | 6% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% |
| Trimethoprim-sulfamethoxazole | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 0% | 1% | 1% | 0% | 0% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 3% | 2% | 1% | 1% | 1% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 1% | 2% | 2% | 1% | 1% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given antimicrobial. |
||||||||||||||||||||||||||||||
Figure 9. Temporal variations in resistance of Salmonella serovars from humans (cont'd)
| Serovar | Paratyphi A and B | Typhi | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | '03 | '04 | '05 | '06 | '07 | '08 | '09 | '10 | '11 | '12 | '03 | '04 | '05 | '06 | '07 | '08 | '09 | '10 | '11 | '12 | |
| Number of isolates | 27 | 43 | 70 | 66 | 45 | 65 | 54 | 30 | 12 | 38 | 127 | 125 | 121 | 164 | 156 | 186 | 160 | 179 | 197 | 144 | |
| Antimicrobial | |||||||||||||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% | 0% | 7% | 2% | 4% | 5% | 4% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% | 16% | 26% | 18% | 21% | 17% | 18% | 16% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17% | |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | 2% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 0% | 0% | 1% | 0% | 0% | 1% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | 2% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.70% | 84% | 74% | 85% | 69% | 72% | 74% | 43% | Significant differences (P ≤ 0.05) for a given antimicrobial.42% | Significant differences (P ≤ 0.05) for a given antimicrobial.95% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44% | 57% | 72% | 80% | 78% | 69% | 78% | 87% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.87% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.84% | |
| Streptomycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% | 0% | 9% | 0% | 4% | 5% | 2% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% | 16% | 27% | 14% | 21% | 18% | 16% | 16% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.25% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16% | |
| Tetracycline | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% | 0% | 10% | 2% | 4% | 6% | 2% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% | 15% | 24% | 10% | 13% | 6% | 6% | 3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | |
| Trimethoprim-sulfamethoxazole | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% | 0% | 3% | 0% | 2% | 2% | 0% | 0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% | 16% | 26% | 15% | 21% | 17% | 16% | 17% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.27% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18% | |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given antimicrobial. |
|||||||||||||||||||||
Figure 9. Temporal variations in resistance of Salmonella serovars from humans (cont'd)
| Serovar | Typhimurium | 4,[5],12:i:- | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | '03 | '04 | '05 | '06 | '07 | '08 | '09 | '10 | '11 | '12 | '03 | '04 | '05 | '06 | '07 | '08 | '09 | '10 | '11 | '12 | |
| Number of isolates | 605 | 597 | 559 | 539 | 658 | 474 | 417 | 452 | 361 | 378 | 42 | 46 | 63 | 57 | 85 | 124 | 186 | 163 | 104 | 122 | |
| Antimicrobial | |||||||||||||||||||||
| Ampicillin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44% | 38% | 44% | 30% | 22% | 31% | 24% | 24% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.25% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% | 15% | 29% | 26% | 16% | 16% | 22% | 35% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.37% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.33% | |
| Ceftiofur | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | 2% | 4% | 1% | 1% | 2% | 2% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% | 0% | 10% | 14% | 6% | 8% | 10% | 9% | Significant differences (P ≤ 0.05) for a given antimicrobial.12% | Significant differences (P ≤ 0.05) for a given antimicrobial.2% | |
| Gentamicin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 2% | 2% | 1% | 2% | 3% | 1% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% | 7% | 2% | 2% | 0% | 5% | 2% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | |
| Nalidixic acid | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | 1% | 3% | 2% | 3% | 2% | 3% | 2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% | 7% | 0% | 4% | 4% | 2% | 1% | 1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% | |
| Streptomycin | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% | 35% | 40% | 36% | 23% | 30% | 26% | 25% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.27% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% | 17% | 24% | 16% | 11% | 15% | 12% | 28% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.23% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31% | |
| Tetracycline | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.47% | 41% | 48% | 38% | 27% | 32% | 28% | 25% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% | 22% | 27% | 25% | 19% | 30% | 33% | 40% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.37% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42% | |
| Trimethoprim-sulfamethoxazole | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% | 7% | 8% | 8% | 5% | 5% | 2% | 4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% | 4% | 5% | 4% | 4% | 2% | 1% | 2% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% | Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% | |
For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given antimicrobial. |
|||||||||||||||||||||
Minimum Inhibitory Concentrations
More details on how to interpret the minimum inhibitory concentrations (MICs) tables are provided in the CIPARS Annual Report 2012 – Chapter 1. Design and Methods.
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 1,179 | <=1 | <=1 | 0.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 Table 2 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Table 2 - Footnote 2 | 0.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Ceftiofur | 1,179 | 1 | 1 | 0.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 Table 2 - Footnote 1 | Table 2 - Footnote 2 | 0.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 1,179 | <=0.25 | <=0.25 | 0.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Table 2 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Table 2 - Footnote 2 | Table 2 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.2 | 0.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Ciprofloxacin | 1,179 | <=0.015 | 0.12 | 0.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Table 2 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4 Table 2 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 | 0.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| II | Ampicillin | 1,179 | <=1 | 2 | 3.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 2 - Footnote 1 | Table 2 - Footnote 2 | 3.5Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Azithromycin | 1,179 | 4 | 4 | 0.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | 0.1 Table 2 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Cefoxitin | 1,179 | 2 | 4 | 0.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 2 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 Table 2 - Footnote 2 | 0.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Gentamicin | 1,179 | 0.50 | 0.50 | 0.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 | Table 2 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | Table 2 - Footnote 2 | 0.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Kanamycin | 1,179 | <=8 | <=8 | 0.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Table 2 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.1 Table 2 - Footnote 2 | 0.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 1,179 | 4 | >32 | 12.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 2 - Footnote 2 | 11.7Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Streptomycin | 1,179 | <=32 | <=32 | 1.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 Table 2 - Footnote 2 | 1.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 1,179 | <=0.12 | <=0.12 | 1.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | Table 2 - Footnote 2 | 1.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| III | Chloramphenicol | 1,179 | 8 | 8 | 0.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.0 Table 2 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Table 2 - Footnote 2 | 0.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Sulfisoxazole | 1,179 | 64 | 128 | 2.3 Table 2 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | 2.3 Table 2 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | |
| Tetracycline | 1,179 | <=4 | <=4 | 2.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.5 Table 2 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 | Table 2 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.1 | 2.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 555 | ≤ 1 | > 32 | 25.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.0 Table 3 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 Table 3 - Footnote 2 | 18.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Ceftiofur | 555 | 1 | > 8 | 27.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Table 3 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3 Table 3 - Footnote 2 | 25.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Ceftriaxone | 555 | ≤ 0.25 | 16 | 27.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.8 | Table 3 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3 Table 3 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.9 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Ciprofloxacin | 555 | ≤ 0.015 | ≤ 0.015 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Table 3 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| II | Ampicillin | 555 | ≤ 1 | > 32 | 33.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Table 3 - Footnote 1 | Table 3 - Footnote 2 | 33.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Azithromycin | 555 | 4 | 4 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 | Table 3 - Footnote 2 | ||||||||||
| Cefoxitin | 555 | 1 | 32 | 25.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 | Table 3 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19.1 Table 3 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.1 | |||||
| Gentamicin | 555 | 0.50 | 1 | 0.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Table 3 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Table 3 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 | |||||
| Kanamycin | 555 | ≤ 8 | ≤ 8 | 0.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 1 | Table 3 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 | ||||
| Nalidixic acid | 555 | 4 | 4 | 0.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Table 3 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4 | ||||||
| Streptomycin | 555 | ≤ 32 | ≤ 32 | 3.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4 Table 3 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.8 | |||
| Trimethoprim-sulfamethoxazole | 555 | ≤ 0.12 | ≤ 0.12 | 2.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.2 Table 3 - Footnote 2 | 2.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| III | Chloramphenicol | 555 | 8 | 8 | 0.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.4 Table 3 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Table 3 - Footnote 2 | 0.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Sulfisoxazole | 555 | 32 | 64 | 2.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 | 2.7 Table 3 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | ||
| Tetracycline | 555 | ≤ 4 | ≤ 4 | 3.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.6 Table 3 - Footnote 1 | Table 3 - Footnote 2 | 3.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 149 | <=1 | <=1 | 6.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Table 4 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7 Table 4 - Footnote 2 | 3.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or "core") surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Ceftiofur | 149 | 1 | 1 | 6.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.8 | Table 4 - Footnote 1 | Table 4 - Footnote 2 | 6.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 149 | <=0.25 | <=0.25 | 6.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Table 4 - Footnote 1 | Table 4 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3 | |||||||||||
| Ciprofloxacin | 149 | <=0.015 | <=0.015 | 0.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 | Table 4 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | Table 4 - Footnote 2 | ||||||||||
| II | Ampicillin | 149 | <=1 | <=1 | 6.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | Table 4 - Footnote 1 | Table 4 - Footnote 2 | 6.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Azithromycin | 149 | 4 | 4 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 | Table 4 - Footnote 2Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| Cefoxitin | 149 | 2 | 2 | 6.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 | Table 4 - Footnote 1 | Table 4 - Footnote 2 | 6.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Gentamicin | 149 | 0.50 | 0.50 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 | Table 4 - Footnote 1 | Table 4 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Kanamycin | 149 | <=8 | <=8 | 2.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.0 | Table 4 - Footnote 1 | Table 4 - Footnote 2 | 2.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 149 | 4 | 4 | 2.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | Table 4 - Footnote 2 | 2.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Streptomycin | 149 | <=32 | <=32 | 8.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.9 | Table 4 - Footnote 2 | 8.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | |||
| Trimethoprim-sulfamethoxazole | 149 | <=0.12 | <=0.12 | 3.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.6 | Table 4 - Footnote 2 | 3.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| III | Chloramphenicol | 149 | 4 | 8 | 7.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.5 Table 4 - Footnote 1 | Table 4 - Footnote 2 | 7.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Sulfisoxazole | 149 | 64 | 128 | 8.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | 8.7 Table 4 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | |
| Tetracycline | 149 | <=4 | <=4 | 9.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90.6 Table 4 - Footnote 1 | Table 4 - Footnote 2 | 9.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 38 | 2 | 2 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.4 | Table 5 - Footnote 1 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Ceftiofur | 38 | 1 | 1 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 5 - Footnote 1 | Table 5- Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Ceftriaxone | 38 | <=0.25 | <=0.25 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Table 5 - Footnote 1 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| Ciprofloxacin | 38 | 0.50 | 0.50 | 2.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Table 5 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6 Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| II | Ampicillin | 38 | 2 | 2 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.7 | Table 5 - Footnote 1 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Azithromycin | 38 | 4 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.1 | Table 5 - Footnote 2Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||||
| Cefoxitin | 38 | 4 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.1 Table 5 - Footnote 1 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Gentamicin | 38 | <=0.25 | <=0.25 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Table 5 - Footnote 1 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Kanamycin | 38 | <=8 | <=8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 5 - Footnote 1 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 38 | >32 | >32 | 94.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.5 Table 5 - Footnote 2 | 84.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Streptomycin | 38 | <=32 | <=32 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 38 | <=0.12 | <=0.12 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.3 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| III | Chloramphenicol | 38 | 8 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.7 Table 5 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.3 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Sulfisoxazole | 38 | 64 | 64 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.6 | Table 5 - Footnote 2Discontinuation or no surveillance activity | |||
| Tetracycline | 38 | <=4 | <=4 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Table 5 - Footnote 1 | Table 5 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 144 | <=1 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.3 Table 6 - Footnote 1 | Table 6 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Ceftiofur | 144 | 0.50 | 1 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.2 | Table 6 - Footnote 1 | Table 6 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 144 | <=0.25 | <=0.25 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 6 - Footnote 1 | Table 6 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||||
| Ciprofloxacin | 144 | 0.25 | 0.50 | 9.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.3 | Table 6 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8 Table 6 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.7 | 6.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| II | Ampicillin | 144 | <=1 | >32 | 16.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.3 | Table 6 - Footnote 1 | Table 6 - Footnote 2 | 16.7Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Azithromycin | 144 | 4 | 4 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1 | Table 6 - Footnote 2Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Cefoxitin | 144 | 4 | 8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.8 Table 6 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Table 6 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Gentamicin | 144 | 0.50 | 0.50 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.7 | Table 6 - Footnote 1 | Table 6 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Kanamycin | 144 | <=8 | <=8 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 | Table 6 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Nalidixic acid | 144 | >32 | >32 | 84.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.7 Table 6 - Footnote 2 | 83.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Streptomycin | 144 | <=32 | >64 | 16.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.0 | Table 6 - Footnote 2 | 16.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 144 | <=0.12 | >4 | 18.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Table 6 - Footnote 2 | 18.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| III | Chloramphenicol | 144 | 8 | >32 | 17.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.7 Table 6 - Footnote 1 | Table 6 - Footnote 2 | 17.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Sulfisoxazole | 144 | 64 | >256 | 18.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 | 0.7 | 18.8 Table 6 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | |
| Tetracycline | 144 | <=4 | <=4 | 0.0 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Table 6 - Footnote 1 | Table 6 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 378 | <=1 | 16 | 1.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 Table 7 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.7 | Table 7 - Footnote 2 | 1.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Ceftiofur | 378 | 1 | 1 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 Table 7 - Footnote 1 | Table 7 - Footnote 2 | 2.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 378 | <=0.25 | <=0.25 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1 | Table 7 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Table 7 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 | 0.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ciprofloxacin | 378 | <=0.015 | 0.03 | 0.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Table 7 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.8 Table 7 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| II | Ampicillin | 378 | <=1 | >32 | 24.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 | Table 7 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 Table 7 - Footnote 2 | 24.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Azithromycin | 378 | 4 | 4 | 0.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 | 0.5 Table 7 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| Cefoxitin | 378 | 2 | 4 | 1.9 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Table 7 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3 Table 7 - Footnote 2 | 0.5Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Gentamicin | 378 | 0.50 | 1 | 3.7 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Table 7 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9 Table 7 - Footnote 2 | 1.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Kanamycin | 378 | <=8 | <=8 | 5.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Table 7 - Footnote 2 | 5.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Nalidixic acid | 378 | 4 | 4 | 2.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 Table 7 - Footnote 2 | 1.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Streptomycin | 378 | <=32 | >64 | 27.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.5 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.3 Table 7 - Footnote 2 | 22.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 378 | <=0.12 | 0.25 | 7.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 Table 7 - Footnote 2 | 6.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| III | Chloramphenicol | 378 | 8 | >32 | 21.4 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.9 Table 7 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9 | Table 7 - Footnote 2 | 21.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Sulfisoxazole | 378 | 64 | >256 | 31.2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 | 31.2 Table 7 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | ||
| Tetracycline | 378 | <=4 | >32 | 29.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.9 Table 7 - Footnote 1 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 Table 7 - Footnote 2 | Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.8 | 14.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| IV | |||||||||||||||||||||
| Antimicrobial | n | Percentiles | % R | Distribution (%) of MICs (µg/mL) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC 50 | MIC 90 | ≤ 0.015 | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | >256 | ||||
| I | Amoxicillin-clavulanic acid | 122 | <=1 | 8 | 2.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.4 Table 8 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | 0.8 Table 8 - Footnote 2 | 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity |
| Ceftiofur | 122 | 1 | 1 | 1.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 8 - Footnote 1 | Table 8 - Footnote 2 | 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Ceftriaxone | 122 | <=0.25 | <=0.25 | 1.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.4 | Table 8 - Footnote 1 | Table 8 - Footnote 2 | 0.8 | 0.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| Ciprofloxacin | 122 | <=0.015 | <=0.015 | 0.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.3 | Table 8 - Footnote 1 | Table 8 - Footnote 2 | 0.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||||
| II | Ampicillin | 122 | <=1 | >32 | 32.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.8 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 | Table 8 - Footnote 1 | Table 8 - Footnote 2 | 32.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Azithromycin | 122 | 4 | 4 | 2.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | 2.5Table 8 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||||
| Cefoxitin | 122 | 2 | 2 | 1.6 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 8 - Footnote 1 | Table 8 - Footnote 2 | 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Gentamicin | 122 | 0.50 | 1 | 0.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.4 | Table 8 - Footnote 1 | Table 8 - Footnote 2 | 0.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| Kanamycin | 122 | <=8 | <=8 | 2.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.7 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Table 8 - Footnote 2 | 2.5Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||
| Nalidixic acid | 122 | 4 | 4 | 0.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.2 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.3 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | 0.8Table 8 - Footnote 2 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| Streptomycin | 122 | <=32 | >64 | 31.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.9 | 0.8Table 8 - Footnote 2 | 30.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Trimethoprim-sulfamethoxazole | 122 | <=0.12 | <=0.12 | 4.1 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | Table 8 - Footnote 2 | 4.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | ||||
| III | Chloramphenicol | 122 | 8 | 8 | 2.5 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41.0 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.7 Table 8 - Footnote 1 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | 0.8Table 8 - Footnote 2 | 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |
| Sulfisoxazole | 122 | 64 | >256 | 30.3 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.9 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 | 30.3Table 8 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | |
| Tetracycline | 122 | <=4 | >32 | 41.8 | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.2 Table 8 - Footnote 1 | Table 8 - Footnote 2 | 41.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or core ) surveillance in the specified year. | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | Discontinuation or no surveillance activity | |||
| IV | |||||||||||||||||||||
Page details
- Date modified: